» Articles » PMID: 28178391

Amino-terminal Enhancer of Split Gene AES Encodes a Tumor and Metastasis Suppressor of Prostate Cancer

Overview
Journal Cancer Sci
Specialty Oncology
Date 2017 Feb 9
PMID 28178391
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

A major cause of cancer death is its metastasis to the vital organs. Few effective therapies are available for metastatic castration-resistant prostate cancer (PCa), and progressive metastatic lesions such as lymph nodes and bones cause mortality. We recently identified AES as a metastasis suppressor for colon cancer. Here, we have studied the roles of AES in PCa progression. We analyzed the relationship between AES expression and PCa stages of progression by immunohistochemistry of human needle biopsy samples. We then performed overexpression and knockdown of AES in human PCa cell lines LNCaP, DU145 and PC3, and determined the effects on proliferation, invasion and metastasis in culture and in a xenograft model. We also compared the PCa phenotypes of Aes/Pten compound knockout mice with those of Pten simple knockout mice. Expression levels of AES were inversely correlated with clinical stages of human PCa. Exogenous expression of AES suppressed the growth of LNCaP cells, whereas the AES knockdown promoted it. We also found that AES suppressed transcriptional activities of androgen receptor and Notch signaling. Notably, AES overexpression in AR-defective DU145 and PC3 cells reduced invasion and metastasis to lymph nodes and bones without affecting proliferation in culture. Consistently, prostate epithelium-specific inactivation of Aes in Pten mice increased expression of Snail and MMP9, and accelerated growth, invasion and lymph node metastasis of the mouse prostate tumor. These results suggest that AES plays an important role in controlling tumor growth and metastasis of PCa by regulating both AR and Notch signaling pathways.

Citing Articles

Bioinformatics Prediction and Machine Learning on Gene Expression Data Identifies Novel Gene Candidates in Gastric Cancer.

Kori M, Gov E Genes (Basel). 2022; 13(12).

PMID: 36553500 PMC: 9778573. DOI: 10.3390/genes13122233.


Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulation.

Yu G, Chen Y, Hu Y, Zhou Y, Ding X, Zhou X Front Cell Dev Biol. 2022; 10:1010639.

PMID: 36438567 PMC: 9692235. DOI: 10.3389/fcell.2022.1010639.


Bmal1 Regulates Prostate Growth via Cell-Cycle Modulation.

Ueda M, Kono J, Sengiku A, Nagumo Y, Mathis B, Shimba S Int J Mol Sci. 2022; 23(19).

PMID: 36232573 PMC: 9569634. DOI: 10.3390/ijms231911272.


as a toolkit to tackle cancer and its metabolism.

Jiang H, Kimura T, Hai H, Yamamura R, Sonoshita M Front Oncol. 2022; 12:982751.

PMID: 36091180 PMC: 9458318. DOI: 10.3389/fonc.2022.982751.


The role of the WNT signaling pathway in the maxillary sinus squamous cell carcinoma.

Bagca B, Biray Avci C, Sezgin B, Veral A, Gode S, Karci H Med Oncol. 2022; 39(4):42.

PMID: 35092507 DOI: 10.1007/s12032-021-01640-5.


References
1.
Singh A, Figg W . In vivo models of prostate cancer metastasis to bone. J Urol. 2005; 174(3):820-6. DOI: 10.1097/01.ju.0000169133.82167.aa. View

2.
Oshima H, Taketo M, Oshima M . Destruction of pancreatic beta-cells by transgenic induction of prostaglandin E2 in the islets. J Biol Chem. 2006; 281(39):29330-6. DOI: 10.1074/jbc.M602424200. View

3.
Clyne M . Prostate cancer: androgen deprivation causes EMT in the prostate. Nat Rev Urol. 2011; 9(1):4. DOI: 10.1038/nrurol.2011.208. View

4.
Kasper S . Survey of genetically engineered mouse models for prostate cancer: analyzing the molecular basis of prostate cancer development, progression, and metastasis. J Cell Biochem. 2004; 94(2):279-97. DOI: 10.1002/jcb.20339. View

5.
Hafeez B, Adhami V, Asim M, Siddiqui I, Bhat K, Zhong W . Targeted knockdown of Notch1 inhibits invasion of human prostate cancer cells concomitant with inhibition of matrix metalloproteinase-9 and urokinase plasminogen activator. Clin Cancer Res. 2009; 15(2):452-9. PMC: 2951134. DOI: 10.1158/1078-0432.CCR-08-1631. View